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Abstract
Background: Within the context of the support program for smoking cessation, initiated by the Turkish Ministry of
Health in 2011, those who present at ‘smoking cessation’ centres and are found to be suitable for pharmacological
treatment are given varenicline and bupropion free of charge. As the smoking cessation programme is centralized,
the selection of the medication is made randomly to provide a fixed distribution rate. The aim of this study was to
evaluate the efficacy of both varenicline and bupropion in smoking cessation and to evaluate the effect of the
smoking cessation programme.
Methods: A total of 405 individuals who met the study criteria were included in the study. Smoking habits and
degree of dependence were determined in all the participants with the Fagerstrom test for nicotine dependence
(FTND) and bupropion or varenicline therapy was initiated in those who were eligible. Patients were followed up at
15 days then at 1, 2, 3, 6 and 12 months after smoking cessation. A level of CO < 5 ppm and ‘point prevalence
abstinence’ were used as the criteria of success for smoking cessation and this evaluation showed the non-smoking
status in the previous 7 days.
Results: The mean age of the participants was 35.19 ± 7.73 years and 82.8% (n = 334) were male. Of the
participants, 60.2% (n = 244) were given varenicline and 39.8% (n = 161) bupropion. The mean FTND and package/
year was not significantly different between the groups. The rates of success in the 1st and 2nd weeks, and 1st, 3rd
and 6th months were significantly higher in the varenicline group than in the bupropion group (p < 0.05). At the
end of one year, the rate of smoking cessation was determined as 13.9% (n = 34) in the varenicline group and 6.2%
(n = 10) in the bupropion gruop. The difference was statistically significant (p = 0.015). At the end of 1 year when
the previous 7 days smoking status was evaluated with the ‘point prevalence abstinence’ measurement as the
success criteria, success rates were 20.5% with varenicline and 18.6% with bupropion and the difference was not
significant (p = 0.646). The individuals who used the medications for 45 days or longer were more successful in
smoking cessation (p < 0.001). The most common reasons given for discontinuing the medication were the side-
effects (31.5%). No significant difference was determined between the groups in respect of the side-effects
observed.
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Conclusions: Although the rates of smoking cessation in all the other control points were higher with varenicline
than with bupropion, no significant difference was found between the success rates of varenicline and bupropion
used in smoking cessation based on the last 7 days at the end of one year. Those who used the medications for
45 days or longer were more successful in smoking cessation.
Keywords: Varenicline, Bupropion, Smoking cessation
Background
Smoking is addictive in nature because of the psycho-
active nicotine substance contained in tobacco. The risk
of dependence in smoking is similar to that in heroin
and alcohol use [1]. Smoking is one of the most import-
ant causes of four diseases which are the most common
causes of mortality (atherosclerotic cardiovascular dis-
ease, cerebrovascular disease, cancer and chronic ob-
structive pulmonary disease) The development of
smoking-related diseases and the associated risks of
death significantly decrease in persons who quit smoking
[2]. Therefore, one should seek help from both the
immediate vicinity and professionals. Pharmacological
support is an important component of smoking cessation
and should be recommended to those want to quit [2–4].
Despite increased understanding of the harmful ef-
fects, smoking has recently become almost an epidemic.
A new tobacco control period was initiated by the
World Health Organization in 2003 within the context
of action against smoking and the Framework Conven-
tion on Tobacco Control (FCTC) contract was pub-
lished. Turkey signed that contract in 2004 and adopted
it in the same year with Law no 5261. In accordance
with that contract, the “National Tobacco Control
Program” and the “Tobacco Control Action Plan” cover-
ing 2008–2012 were prepared with the participation of a
large number of representatives from official and non-
governmental organizations. Vareniclin tartrate (Champix
©) and bupropion hydrochloride (Zyban ©) which are
used in smoking cessation were distributed free of charge
in the smoking cessation clinics (SCC) for a 3-month
period [5]. This increased applications to smoking cessa-
tion clinics. During this period, that there was an increase
of 8.8 fold in the number of applications to our clinic was
an encouraging finding in favour of the campaign. Patients
who were to receive the medication were randomly deter-
mined by the medication support center in order to pro-
vide a constant distribution rate of varenicline and
bupropion and so that physicians would not be aware of
the medication distribution. This created an open experi-
mental setup for comparison of the rate of success
between varenicline and bupropion.
In this context, the aim of the study was to evaluate
the efficacy of both varenicline and bupropion in the
cessation of smoking and the effect of the smoking
cessation programme. In addition, compliance of indi-
viduals to using the medications and side effects were
evaluated.
Methods
Our polyclinic has been in service since 1999, providing
behavioural therapy support with a biopsychosocial
approach to individuals wishing to stop smoking and
recommending pharmacological methods and where
possible monitoring the patients with proactive tele-
phone calls and follow-up visits. Patients can apply to
the clinic directly by calling the Ministry of Health ‘stop
smoking’ helpline and making an appointment.
This study was designed as a prospective, comparative
study. During the study period of March 2011-October
2011, a total of 2397 individuals aged over 18 years
applied to our smoking cessation polyclinic and were
included in the smoking cessation programme of the
Ministry of Health. After smoking cessation, the partici-
pants were evaluated at 15 days then at 1, 2, 3, 6 and
12 months. Patients who did not attend the follow-up
visits were called by telephone. A total of 405 individuals
completed one year of follow-up and agreed to participate
in the study.
A questionnaire was completed at face-to-face inter-
views. The questionnaire included sociodemographic
characteristics of the participants and questions related
to alcohol consumption (unit/day; 1 unit alcohol = 1glass
of wine, 1 bottle of beer, 1 measure of spirits), smoking
status since stopping, medication use and if used irregu-
larly, the reasons why (patients were not guided in this),
side-effects, confidence in their ability to be successful
in smoking cessation (0–5 points;0: no, 1: very low, 2:
low, 3:medium; 4:high, 5:very high), whether or not there
was another smoker at home, support from family and
friends and previous attempts to stop smoking. In
addition to the physical examination, the Fagerstrom
Test for Nicotine Dependence (FTND) was applied [6].
In the period of medication support, the medicines to
be used by patients specifically in this period were
distributed free of charge by the Ministry of Health.
Persons considered eligible after presentation were given
one of the two medications (varenicline or bupropion)
by the support center. Since nicotine replacement was
not included in the program, this study only evaluated
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the bupropion and vareniclin therapies. The partici-
pants were informed about the frequent possible side
effects of the medications. Of the total participants, 60.2%
(n = 244) were given vareniclin and 39.8% (n = 161) bupro-
pion. Patients receiving treatment for previously known
psychiatric disease and those with epilepsy were excluded
from the study.
Fagerstrom Test for Nicotine Dependence (FTND)
FTND is a widely used scale in the determination of nico-
tine dependence. The Turkish version of FTND has been
tested for reliability. FTND consists of 6 questions scored
between 1 and 10 points with a score of > 4 points indicat-
ing the possibility of dependence. Based on the total score
obtained from a comprehensive evaluation of this test;
nicotine dependence is graded in 5 categories as very low
(0–2 points), low (3–4 points), medium (5 points), high
(6–7 points) and very high (8–10 points) [6].
Evaluation of side effects
Questions were asked about the possible side effects
to achieve a standard conclusion and to learn if there
were side effects that the patients could not recall,
but might have experienced. In addition, other side
effects reported by the patients were recorded and the side
effects specified by the patients were combined if they
were very similar.
Measurement of CO level in breath
The monitoring of smoking status was implemented by
measuring the CO level in the breath using a ‘Bedfont-
pico + Smokerlyzer’ monitor in the clinic at every visit.
In the CO measurement in the breath, participants were
first asked to perform a forced expiration and then a full
inhalation following by holding their breath until a beep
sound from the device (about 15 s) and then to blow
slowly into the mouthpiece, aiming to empty the lungs
completely. For subjects who reported that they had not
smoked in the previous 7 days, the CO measurements
were performed twice at 5 min intervals. A level between
6 and 10 ppm indicated an infrequent smoker or danger
zone, while 11 ppm and higher values indicated an
addicted smoker with high levels of CO in their blood.
In the present study, a CO level ≤5 ppm was considered
as the success criterion as proposed by Perkins et al. [7].
The ‘point prevalence abstinence’ measurement, as
in the American Public Health Service guidelines, was
used to determine the success rate in smoking cessa-
tion [8]. This evaluation expresses the smoking status
in the previous 7 days and has been widely used in
previous studies as it provides a general result and
increases statistical power [9].
Statistical analysis
Statistical analysis of the data was performed utilizing the
SPSS v20.0 Statistical Software. Definitive statistics were
expressed as mean rank and difference for continuously
measured variables and as frequency and percentage for
nominal variables. Relationships between variables were
evaluated using correlation analysis. The Chi-square test
was used for categorical variables, while variables specified
with measurement were evaluated through the Independ-
ent Samples t-test. A value of p < 0.05 was considered
statistically significant.
Approval for this study was granted by the Local Ethics
Committee.
Results
Of the total 405 participants, 82.5% (n = 334) were male
and 17.5% (n = 71) female. The age of the patients
ranged from 20 to 65 years. The overall mean age was
35.24 ± 7.7 years, while the mean age was 35.09 ±
7.85 years in males and 36.03 ± 6.88 years in females
(Table 1). The mean FTND value at presentation was
determined as 6.34 ± 2.38 for varenicline and 6.23 ± 2.49
for bupropion (p = 0.655), while package/year values
were 14.8 ± 7 and 15.9 ± 6, respectively (p = 0.624).
At the end of one year, the success rate was found to
be 20.5% with varenicline and 18.6% with bupropion
based on 7-day point prevalence (p = 0.646). In persons
who used the medications for 45 days or longer, the
one-year success rates were determined as 27.6 and
27.8% for varenicline and bupropion based on 7-day
point prevalence (p = 0.987). The CO levels of all the
participants were measured and found to be <5 ppm in
80 participants who stated that they had not smoked
during the previous week (mean CO level, 2.36 ± 0.90).
Of the total participants, 3.95% (n = 16) never used the
medication, while 6.7% (n = 27) used the medication
regularly. Regular use of the medication over 90 days was
determined in 9.8% (n = 24) of the varenicline users and
1.9% (n = 3) of the bupropion users (p= 0.002). Medication
use of 71 days or longer was determined in 34 (13.7%) vare-
nicline and 6 (3.7%) bupropion users (p= 0.001). The rate of
medication use for at least 45 days was determined as 25.9%
(n = 105) (varenicline; n = 87, bupropion; n = 18) (p < 0.001).
The demographic characteristics and smoking habits of
the participants are shown in Table 1. No significant
differences were observed between the groups in respect
of gender, age, marital status, educational level, BMI, pres-
ence of another smoker at home, alcohol consumption,
social support, previous quitting attempts, concerns about
the harmful effects of smoking, Fagerstrom scores or the
age of starting to smoke. However, there was a significant
difference between the groups in terms of the amount of
smoking, with a higher rate determined in the varenicline
group than in the bupropion group (p = 0.004).
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Based on the patient self, the period with the high-
est rate of success was the first two weeks after the
day of cessation. The rates of success in the first and
second weeks were significantly different in favour of
varenicline (p < 0.001). The rate of success in the first
month was determined as 48.4% in varenicline and
33.5% in bupropion users (p = 0.003). When the sub-
jects who did not smoke in the first 3 months were
evaluated, the varenicline users were found to be
significantly more successful than the bupropion users
(p = 0.003). The difference between the two groups
continued at the end of 6 months and at the end of one
year, the rate of the smoking cessation was found to be
13.9% (n = 34) in the varenicline group and 6.2% (n = 10)
in the bupropion group with a statistically significant
difference (p = 0.015) (Table 2).
Open-ended questions were asked about the reasons
for taking the medication, but not using it regularly and
the answers given were categorized. Those who partici-
pated in the campaign because it was free of charge
although they did not feel ready to quit smoking or did
not believe that the medication would be effective were
determined at the rate of 10.1%. After exclusion of 27
individuals who used the medications regularly, the final
assessment was applied to 378 participants. The first or
the most remarkable reasons reported by the partici-
pants are given in Table 3 in order of frequency. Accord-
ing to this, 30% of those using varenicline and 33.5% of
Table 1 The demographical characteristics and smoking habits of participants
Variable Varenicline (n = 244) Bupropion (n = 161) p*
n % n %
Gender Male (n = 334) 194 79.5 140 87.0 0.054
Female (n = 71) 50 20.5 21 13.0
Age Groups 20–29 (n = 111) 74 30.3 37 23.0 0.267
30–39 (n = 184) 106 43.4 78 48.4
≥40 (n = 110) 64 26.2 46 28.6
Marital Status Married (n = 329) 191 78.3 138 85.7 0.061
Not Married (n = 76) 53 21.7 23 14.3
Educational Status Primary- Secondary 45 18.4 31 19.3 0.775
High School 101 41.4 71 44.1
College + a 98 40.2 59 36.6
Alcohol Consumption Status Yes (n = 63) 37 15.2 26 16.163 0.789
No (n = 342) 207 84.8 135 83.9
Social support Yes (n = 241) 169 69.3 75 65.2 0.394
No (n = 161) 75 30.7 86 34.8
The amount of cigarettes smoked per day in
the initial presentation
1–10 pcs 29 11.9 5 3.1 0.004
11–20 pcs 99 40.6 86 53.4
21–30 pcs 79 53.4 43 26.7
≥31 pcs 37 45.7 27 16.8
Previous quitting trial Yes (n = 272) 167 68.4 105 65.2 0.499
No (n = 133) 77 31.6 56 34.8
Concerns about the harmful effects of smoking No (n = 24) 16 6.6 8 5.0 0.532
Little (n = 69) 45 18.4 24 14.9
High (n = 170) 96 39.3 74 46.0
Very High (n = 142) 87 35.7 55 34.2
Mean Fagerstrom Score 6.34 ± 2.38 6.23 ± 2.49 0.655**
The amount of cigarettes/day in the initial presentation 22.78 ± 10.11 23.39 ± 9.13 0.540
Mean Age 34.8 ± 7.61 35.9 ± 7.78 0.124
Mean age of start to begin smoking 17.80 ± 4.26 17.60 ± 4.35 0.635
Mean Body Mass Index 25.46 ± 3.80 26.11 ± 3.59 0.082
*Chi square test, **Independent sample t test (in evaluation of mean values)
aCollege graduate or bachelor’s degree
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those using bupropion, stated side effects as the reason
for not using the medication regularly. With the excep-
tion of 16 subjects who never used the medications,
62.2% (n = 242) of the remaining 389 individuals re-
ported that they developed at least one side effect. Of
the total 234 varenicline users, 143 (61.1%) reported that
they experienced at least one side effect, while this rate
was 98 (63.2%) of 155 bupropion users (p = 0.674). The
5 most common side effects were nausea, insomnia,
headache, fatigue, irritability and the 5 side effects most
commonly self-reported in the study were insomnia,
nausea, irritability, headache and dry mouth.
When the factors affecting the success of smoking
cessation were evaluated in 80 participants who quit
smoking, the rate of success was higher among those
who did not drink alcohol, used the medication for
45 days or longer or had experienced multiple failed
attempts to quit smoking (p < 0.05). The cessation of
smoking rate in the previous 7 days of those who used
the medications for 45 days or more was 27.6% in the
varenicline group and 27.8% in the bupropion group. No
significant differences were observed between the groups
in respect of other parameters (Table 4).
Dıscussıon
In this study, the overall success rate of both medica-
tions in smoking cessation was found to be 19.8% at the
end of the first year. Based on the patient statements,
the uninterrupted rate of cessation (URC) of varenicline
was found to be higher in the first month, in the first
three months, 5–12 weeks, in the first 6 months and the
entire year. At the end of one year, the rate of smoking
cessation was determined as 13.9% in the varenicline
group and 6.2% in the bupropion group. However, when
the ‘point prevalence abstinence’ measurement of the
American Public Health Service guidelines, was used as
the criteria of success in smoking cessation in the previ-
ous 7 days at the end of 1 year, the rate of success was
determined as 20.5% for varenicline and 18.6% for
bupropion. No statistically significant difference was
found between the medications.
In a systematic review by Cahill et al., varenicline was
superior to single forms of NRT (OR 1.57; 95% CI, 1.29 to
1.91), and to bupropion (OR 1.59; 95% CI, 1.29 to 1.96),









n % n % n %
First week 158 64.8 75 46.6 233 57.5 <0.001
First 2 weeks 143 58.6 63 39.1 206 50.9 <0.001
First 1 month 118 48.4 54 33.5 172 42.5 0.003
First 3 months 76 31.1 29 18.0 105 25.9 0.003
First 6 months 48 19.7 16 9.9 64 15.8 0.009
First 1 year 34 13.9 10 6.2 44 10.9 0.015
*Chi-square test
Table 3 Comparisons of causes of irregular medication usage of groups





n % n %
Side effects 66 30 53 33.5 0.464
Over self-confidence/no more need for medicationthe drug 48 21.8 17 10.8 0.005
Not to see any effect of the drugmedication 14 6.4 21 13.3 0.022
Not feel exactly ready to quit smoking 14 6.4 16 10.1 0.182
Fail to quit smoking 18 8.2 6 3.8 0.085
Begin to smoke again 14 6.4 8 5.1 0.594
Fear of side effects 10 4.5 6 3.8 0.722
Inability to come controls 7 3.2 7 4.4 0.526
Not to believe effect of the medicationdrug 6 2.7 5 3.2 0.803
Increased in desiremand to smoke 4 1.8 4 2.5 0.635
ThinkDesire to quit the to not to take the medication anddrug smoking
at the same dday of smoking cessation
3 1.4 4 2.5 0.406
Work schedule 3 1.4 1 0.6 0.493
Since the drug is bupropion 0 0 4 2.5 0.018
ToNot dis like using medicationine 2 0.9 0 0 0.229
Not to take the drug with them 1 0.5 2 1.3 0.381
Noncompliant 10 4.5 4 2.5 0.307
*Chi square test
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but was not more effective than combination NRT (OR
1.06; 95% CI, 0.75 to 1.48) [10]. However, in that review,
the outcome for benefit was continuous or prolonged ab-
stinence for at least six months from the start of treatment
[11]. In meta-analyses by Hughes et al. [12] good results
were found to be related to varenicline compared to
bupropion. In another systematic review which examined
10 studies, findings suggested that varenicline groups
achieved higher rates of abstinence compared to both
NRT and placebo, bupropion and NRT were of similar
effectiveness, and bupropion and varenicline both had
higher abstinence rates compared to placebo [13]. No
statistically significant difference in terms of side effects
was seen in either medication.
CO measurement is frequently used to confirm smok-
ing cessation. In a recent study, a CO titer of 5 ppm was
stated to be the most optimal value containing both
sensitivity and specificity [7]. Likewise in the present
study, a CO level ≤5 ppm was accepted as the criterion
of success. In the current study, the rate of success based
on 7-day point prevalence was found to be 20.5 and
18.6% for varenicline and bupropion, respectively. The
difference was not statistically significant. In literature,
1-year rates of success based on 7-day point prevalence
have been reported as 26.2 and 30.5% for varenicline
and between 20.7 and 35% for bupropion [14–16].
In previous studies about smoking cessation, the mean
age has ranged between 37.8 and 46.2 years [17–19].
Although there have been national and international
studies reporting that age does not influence smoking
cessation outcomes [17, 20], some studies have found
that an older age has a positive influence on the success
of smoking cessation [12, 14–21]. The relatively lower
mean age in the current study may be a factor in the
lower success rate of cessation.
In this study, the rate of regular medication use over
3 months was 6.7%. In a previous study evaluating the
use of varenicline therapy, 28.2% of the participants
continued the therapy for 3 months. In the same study,
the rate of success was significantly higher in the group
which received therapy for 3 months or longer [22]. In a
study by Sheffer et al., the rate of completion of 3-
month therapy was 40% and the successful use of the
therapy was found to be associated with maintaining
communication [23]. Proactive calls have been shown to
increase the rate of success [24]. Low compliance to
treatment is remarkable in the current study. This might
have resulted from the great number of submissions in
the campaign period and the lack of proactive calls. In
the current study, the rate of success was significantly
higher in those who used the medication for longer than
45 days. In a study by Stapleton et al., the 6-month
uninterrupted success rate of participants who com-
pleted the therapy was determined as 37.9%, while this
rate was only 15.6% in those who discontinued the
medication early. In this respect, it can be said that the
current study is in parallel with literature [25].
When the subjects who used the medications for
45 days or longer were evaluated, the one-year success
rate based on 7-day point prevalence was similar be-
tween the groups. In literature, the one-year success rate
based on 7-day point prevalence has been reported as
26.2–30.5% for varenicline and 20.7–35% for bupropion.
The results of the current study are consistent with
literature in this respect [18, 20, 21].
In the current study, 31.5% of the participants re-
ported that they stopped using the medications because
of side effects. No statistically significant difference was
observed between the two medications in terms of side
effects and quitting the medication because of side
effects. In a systematic review by Lei et al. [11] discon-
tinuation because of adverse events (RR, 1.34;95% CI,
1.02–1.75) was significantly more common for the non-
NRT group, which experienced more serious adverse
Table 4 Parameters that considered to effect quitting success
Parameters n % P*
Gender Male (n = 334) 61 18.3 0.102
Female (n = 71) 19 26.8
Age 20–29 (n = 111) 28 25.2 0.234
30–39 (n = 184) 33 17.9
≥40 (n = 110) 19 17.3
Marital status Married (n = 329) 64 19.5 0.752
Not married (n = 76) 16 21.1
Education Primary, secondary, high
school (n = 248)
42 16.9 0.804
University (n = 157) 38 24.2
Alcohol consumption Yes (n = 63) 5 7.9 0.01
No (n = 342) 75 21.9
Social support Yes (n = 274) 50 18.2 0.271
No (n = 131) 30 22.9
Previous quitting attempts ≤1 time (n = 133) 41 15.5 0.003
>1 time (n = 272) 39 27.7
Concern about harmful
effects of smoking
No (n = 24) 8 33.3 0.028
Little (n = 69) 19 27.5
High (n = 170) 34 20.0
Very high (n = 142) 19 13.4
Receiving medication ≥45 days (n = 105) 29 27.6 0.019
<45 days (n = 300) 51 17.0
Self-confidence about
quitting
0–4 points (n = 303) 52 17.2 0.024
5 points (n = 102) 28 27.5
Another person smoking
in house
Yes (n = 142) 29 20.4 0.804
No (n = 263) 51 19.4
*Chi square test
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events (RR, 1.87; 95% CI, 1.08–3.24), compared with the
control group. As NRT was not used in the current
study, a comparison could not be made. Other reasons
for not using the medications regularly were lack of con-
fidence in oneself and belief that there was no further
need of treatment (21.8%) in the varenicline group and
not seeing any benefit from the medication use (13.3%)
in the bupropion group. However, the rate of persons
who joined the campaign because it was free of charge
although they did not feel ready to quit smoking or did
not believe that the medication would be effective was
10.1%. In a previous study, the most important reason
for discontinuation of the medication was starting
smoking again (41.6%) [26]. Other common causes in-
cluded side effects of the medication and the belief
that no further treatment was required. The rate of
smoking has been reported to be high among alcohol
and substance abusers which makes smoking cessa-
tion difficult [27]. In the current study, smoking
cessation was achieved by 5 (7.9%) alcohol abusers
and 21.9% of individuals who did not drink alcohol
and the difference was statistically significant.
It has been reported in literature that those who are
confident in their ability to quit smoking are more
successful [28]. Consistent with the literature, subjects in
the current study with self-confidence about smoking
cessation were found to be more successful. According to
Prochaska [29] and Hymowitz [30], the more attempts
that are made to quit smoking, the higher the rate of
success will be. Similarly in the current study, the differ-
ence in the rate of success was statistically significant in
respect of the number of attempts to quit smoking.
Although the results of this study are in parallel with
reports in literature, there were some limitations to the
study. The sudden increase in patient numbers due to
the campaign and not being able to make sufficient pro-
active follow-up calls for continuous monitoring can be
considered to have seriously reduced the success rates.
Despite giving the patients appointment cards for the
follow-up visits and emphasising the importance of
those monitoring visits, the rate of those attending
follow-up visits remained low. The significant factors for
this situation were found to be the over-subscription of
patients in the campaign period, a single doctor was
attending a large number of patients and that proactive
follow-up telephone calls could not be made. Previous
studies have shown that proactive calls in the support
of smoking cessation were related to an increase in
success rates [24, 31, 32].
Conclusıon
At the end of the first year, no significant difference was
found between the medications in terms of the success
of smoking cessation. The rate of success of both the
medications was consistent with literature. Persons who
used the medications for longer than 45 days were more
successful than those used them for shorter periods. In
this study, the rate of compliance to treatment was lower
compared to previous reports in literature. This may be
attributable to the participation of the individuals without
fully matured thoughts of quitting, purely because of the
free-of charge distribution of the medications and also the
low mean age of the participants. The lack of proactive calls
might also have been a factor affecting compliance. The
free of charge smoking cessation program launched by
the Ministry of Health has created awareness. Although
no significant difference was observed between the
medications in terms of smoking cessation, the very
low compliance to treatment suggests that such cam-
paigns should be re-organized using different strategies.
Abbrevıatıons
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